ResMed Inc. dismissed KPMG LLP as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) effective August 13, 2026, for the fiscal year ending June 30, 2027. The transition was part of a competitive review process with no disagreements or reportable events involving KPMG during the past two fiscal years and interim period. Additionally, director Ronald Taylor announced his retirement from the Board effective at the upcoming Annual Meeting on November 18, 2026, following over 21 years of service. The Board appointed Carol Burt as Lead Director, effective November 15, 2026, succeeding Mr. Taylor. These changes are not due to any disagreements with ResMed regarding operations or accounting principles. ResMed Inc. operates in the health technology industry, creating AI-powered digital health solutions and cloud-connected devices for home healthcare focused on sleep and breathing.

ResMed Inc. reported fourth quarter fiscal year 2026 results with revenue increasing 9% to a record $1.5 billion, up 8% on a constant currency basis. GAAP diluted earnings per share rose 2% to $2.64, while non-GAAP diluted EPS increased 16% to $2.95. For the full fiscal year, revenue grew 10% to $5.7 billion, and GAAP diluted EPS reached $10.43. The company generated $1.8 billion in operating cash flow and returned over $1.0 billion to shareholders through buybacks and dividends during FY2026. ResMed also announced a 10% increase in its quarterly cash dividend to $0.66 per share, with a record date of August 20, 2026, and payment on September 24, 2026. Additionally, the company completed the acquisition of Noctrix Health and announced an agreement to sell its MatrixCare business. ResMed Inc. develops medical devices and software solutions for sleep apnea, respiratory conditions, and sleep health.